Switch theme
Sign up to access all valuation multiples
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
2014
164
LTM Revenue $55.4M
LTM EBITDA -$53.6M
$202M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
scPharmaceuticals has a last 12-month revenue (LTM) of $55.4M and a last 12-month EBITDA of -$53.6M.
In the most recent fiscal year, scPharmaceuticals achieved revenue of $36.3M and an EBITDA of -$77.6M.
scPharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See scPharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $55.4M | XXX | $36.3M | XXX | XXX | XXX |
| Gross Profit | $39.0M | XXX | $25.0M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | -$53.6M | XXX | -$77.6M | XXX | XXX | XXX |
| EBITDA Margin | -97% | XXX | -213% | XXX | XXX | XXX |
| EBIT | -$58.7M | XXX | -$64.8M | XXX | XXX | XXX |
| EBIT Margin | -106% | XXX | -178% | XXX | XXX | XXX |
| Net Profit | -$70.8M | XXX | -$85.1M | XXX | XXX | XXX |
| Net Margin | -128% | XXX | -234% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, scPharmaceuticals's stock price is $4.
scPharmaceuticals has current market cap of $207M, and EV of $202M.
See scPharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $202M | $207M | XXX | XXX | XXX | XXX | $-1.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, scPharmaceuticals has market cap of $207M and EV of $202M.
scPharmaceuticals's trades at 5.6x EV/Revenue multiple, and -2.6x EV/EBITDA.
Equity research analysts estimate scPharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
scPharmaceuticals has a P/E ratio of -2.9x.
See valuation multiples for scPharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $207M | XXX | $207M | XXX | XXX | XXX |
| EV (current) | $202M | XXX | $202M | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | 5.6x | XXX | XXX | XXX |
| EV/EBITDA | -3.8x | XXX | -2.6x | XXX | XXX | XXX |
| EV/EBIT | -3.4x | XXX | -3.1x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.9x | XXX | -2.4x | XXX | XXX | XXX |
| EV/FCF | -3.4x | XXX | -2.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialscPharmaceuticals's last 12 month revenue growth is 84%
scPharmaceuticals's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
scPharmaceuticals's rule of 40 is -255% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
scPharmaceuticals's rule of X is 113% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for scPharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 84% | XXX | 89% | XXX | XXX | XXX |
| EBITDA Margin | -97% | XXX | -213% | XXX | XXX | XXX |
| EBITDA Growth | -47% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -255% | XXX | -129% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 113% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 247% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
scPharmaceuticals acquired XXX companies to date.
Last acquisition by scPharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . scPharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was scPharmaceuticals founded? | scPharmaceuticals was founded in 2014. |
| Where is scPharmaceuticals headquartered? | scPharmaceuticals is headquartered in United States of America. |
| How many employees does scPharmaceuticals have? | As of today, scPharmaceuticals has 164 employees. |
| Who is the CEO of scPharmaceuticals? | scPharmaceuticals's CEO is Mr. John H. Tucker. |
| Is scPharmaceuticals publicy listed? | Yes, scPharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of scPharmaceuticals? | scPharmaceuticals trades under SCPH ticker. |
| When did scPharmaceuticals go public? | scPharmaceuticals went public in 2017. |
| Who are competitors of scPharmaceuticals? | Similar companies to scPharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of scPharmaceuticals? | scPharmaceuticals's current market cap is $207M |
| What is the current revenue of scPharmaceuticals? | scPharmaceuticals's last 12 months revenue is $55.4M. |
| What is the current revenue growth of scPharmaceuticals? | scPharmaceuticals revenue growth (NTM/LTM) is 84%. |
| What is the current EV/Revenue multiple of scPharmaceuticals? | Current revenue multiple of scPharmaceuticals is 3.6x. |
| Is scPharmaceuticals profitable? | Yes, scPharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of scPharmaceuticals? | scPharmaceuticals's last 12 months EBITDA is -$53.6M. |
| What is scPharmaceuticals's EBITDA margin? | scPharmaceuticals's last 12 months EBITDA margin is -97%. |
| What is the current EV/EBITDA multiple of scPharmaceuticals? | Current EBITDA multiple of scPharmaceuticals is -3.8x. |
| What is the current FCF of scPharmaceuticals? | scPharmaceuticals's last 12 months FCF is -$59.8M. |
| What is scPharmaceuticals's FCF margin? | scPharmaceuticals's last 12 months FCF margin is -108%. |
| What is the current EV/FCF multiple of scPharmaceuticals? | Current FCF multiple of scPharmaceuticals is -3.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
